Clinical Trial Update: A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update examining pembrolizumab with carboplatin and gemcitabine in metastatic triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Gemzar (gemcitabine)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Carcinoma Breast Stage IV | Phase 2 | Status: ACTIVE_NOT_RECRUITING